Bacterial Glycosyltransferase Inhibitors as Anti-virulence Compounds
Description:NleB1 is an important virulence factor expressed by multiple bacteria including enterohemorrhagic Escherichia coli (EHEC), enteropathogenic E. coli (EPEC), and Salmonella enterica. These bacteria are of significance to human health as they all cause infectious diarrhea. EHEC causes hemorrhagic colitis and hemolytic uremic syndrome. Researchers at Kansas State University, in collaboration with researchers at University of Kansas, have characterized the NleB1 glycosyltransferase because of its proven importance to human E. coli infections. They have since shown that inhibiting NleB1 activity may be efficacious in preventing and treating bacterial infections. Two NleB1 inhibitors were identified using an optimized high-throughput screening (HTS) assay. These compounds do not inhibit the mammalian glycosyltransferase OGT. These NleB1 inhibitors may have utility as anti-virulence compounds. Advantages:Toxicity – Compounds do not appear to be toxic to mammalian cellsInhibition - These compounds do not inhibit the mammalian glycosyltransferase OGTTreatment - These compounds, or their chemical derivatives, have utility in preventing and/or treating E. coli and Salmonella infections.Applications:Treatment of bacterial infections Hemorrhagic colitisHemolytic uremic syndromePatent Status: Provisional patent application filed in April 2018.Kansas State University Research Foundation seeks to have discussions with companies that are interested in licensing and/or research collaborations.Interested parties should contact:Kansas State University Institute for Commercialization (KSU-IC)2005 Research Park Circle Manhattan, KS 66502Tel: 785-532-3900 Fax: 785-532-3909E-Mail: ic@k-state.edu
美國
